BMRN – Spotlight on Biomarin

We have talked about BioMarin several times before( #1,  #2 and #3). Today, we wanted to put out a brief note on some recent options activity we have noticed. On Friday, we saw some very large options activity that is certainly worth mentioning. The largest trade that happened was a 3-way trade, that does not appear tied […]

INCY – Incyte: Taking The Long View

The pain has not stopped for INCY shareholders since the company offered disappointing revenue guidance in its 2Q conference call August 2. A less than stellar projection of $120 to $135 million in 2012 Jakafi sales did not sit well with investors. This was compounded by the company’s decision to switch mid-year from a sell-through accounting method to […]

XNPT – What’s going on at Xenoport

Many market commentators have been amazed by the recent move in Xenoport(NASDAQ: XNPT), which is up more than 100% since April. Much of this move is easily explained by excitement for their early-stage drug, XP23829. As we will explain below, there appears to be good rationale for this move and likely a move higher. XP23829 […]

SRPT – Sarepta – Approaching Major Catalyst

Sarepta’s release of positive interim data from its DMD drug on July 24 has lit a fire under the stock- and stoked animated discussion in the twitterverse. We revisit this story as a critical catalyst approaches. Due to the severity of the disease and the young age of those afflicted, investors uniformly cheer for eteplirsen, Sarepta’s […]

SNMX – Senomyx shareholders need a bitter-blocker

Senomyx $SNMX is a company that uses biotechnology to develop novel flavor ingredients for the global food and beverage industry [see our initiation report for a detailed profile, and see the 2q-2012 news release for current status of each program]. We thought shares were attractively valued then, but SNMX has continued it’s steady downward slide ever since, […]

ESMO12 Abstracts of interest

The European Society for Medical Oncology (ESMO) Congress 2012 kicks off on September 28th thru October 2nd. Abstract titles are currently able to be viewed and searched here(link), but no other descriptive information is available. Abstracts will be available before-hand on September 17th, with late-breaking abstracts coming during the Congress. Synta Pharmaceuticals (NASDAQ: SNTA) Several sources […]